|
Gene: HSCB |
Gene summary for HSCB |
Gene summary. |
Gene information | Species | Human | Gene symbol | HSCB | Gene ID | 150274 |
Gene name | HscB mitochondrial iron-sulfur cluster cochaperone | |
Gene Alias | DNAJC20 | |
Cytomap | 22q12.1 | |
Gene Type | protein-coding | GO ID | GO:0006790 | UniProtAcc | B0QYH2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
150274 | HSCB | LZE4T | Human | Esophagus | ESCC | 1.87e-03 | 1.09e-01 | 0.0811 |
150274 | HSCB | LZE7T | Human | Esophagus | ESCC | 5.98e-05 | 2.00e-01 | 0.0667 |
150274 | HSCB | LZE8T | Human | Esophagus | ESCC | 2.32e-04 | 1.39e-01 | 0.067 |
150274 | HSCB | LZE24T | Human | Esophagus | ESCC | 3.37e-18 | 4.40e-01 | 0.0596 |
150274 | HSCB | LZE6T | Human | Esophagus | ESCC | 9.10e-06 | 1.67e-01 | 0.0845 |
150274 | HSCB | P1T-E | Human | Esophagus | ESCC | 1.82e-06 | 5.02e-01 | 0.0875 |
150274 | HSCB | P2T-E | Human | Esophagus | ESCC | 5.18e-27 | 3.88e-01 | 0.1177 |
150274 | HSCB | P4T-E | Human | Esophagus | ESCC | 8.19e-24 | 6.22e-01 | 0.1323 |
150274 | HSCB | P5T-E | Human | Esophagus | ESCC | 2.50e-08 | 1.07e-01 | 0.1327 |
150274 | HSCB | P8T-E | Human | Esophagus | ESCC | 1.13e-24 | 4.75e-01 | 0.0889 |
150274 | HSCB | P9T-E | Human | Esophagus | ESCC | 3.13e-16 | 4.74e-01 | 0.1131 |
150274 | HSCB | P10T-E | Human | Esophagus | ESCC | 1.57e-34 | 5.93e-01 | 0.116 |
150274 | HSCB | P11T-E | Human | Esophagus | ESCC | 6.13e-10 | 3.32e-01 | 0.1426 |
150274 | HSCB | P12T-E | Human | Esophagus | ESCC | 3.50e-35 | 4.92e-01 | 0.1122 |
150274 | HSCB | P15T-E | Human | Esophagus | ESCC | 1.63e-19 | 4.38e-01 | 0.1149 |
150274 | HSCB | P16T-E | Human | Esophagus | ESCC | 7.29e-17 | 3.26e-01 | 0.1153 |
150274 | HSCB | P17T-E | Human | Esophagus | ESCC | 2.98e-04 | 3.18e-01 | 0.1278 |
150274 | HSCB | P19T-E | Human | Esophagus | ESCC | 3.14e-03 | 4.08e-01 | 0.1662 |
150274 | HSCB | P20T-E | Human | Esophagus | ESCC | 1.85e-16 | 4.00e-01 | 0.1124 |
150274 | HSCB | P21T-E | Human | Esophagus | ESCC | 1.53e-21 | 2.11e-01 | 0.1617 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00162261 | Oral cavity | LP | iron-sulfur cluster assembly | 15/4623 | 26/18723 | 3.34e-04 | 3.34e-03 | 15 |
GO:00311631 | Oral cavity | LP | metallo-sulfur cluster assembly | 15/4623 | 26/18723 | 3.34e-04 | 3.34e-03 | 15 |
GO:000679012 | Oral cavity | LP | sulfur compound metabolic process | 106/4623 | 339/18723 | 3.36e-03 | 2.25e-02 | 106 |
GO:00974281 | Oral cavity | LP | protein maturation by iron-sulfur cluster transfer | 9/4623 | 16/18723 | 6.82e-03 | 3.94e-02 | 9 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HSCB | SNV | Missense_Mutation | rs773726014 | c.85N>A | p.Asp29Asn | p.D29N | Q8IWL3 | protein_coding | tolerated(1) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HSCB | SNV | Missense_Mutation | novel | c.507T>A | p.Asn169Lys | p.N169K | Q8IWL3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
HSCB | deletion | Frame_Shift_Del | c.363delG | p.Thr122ProfsTer3 | p.T122Pfs*3 | Q8IWL3 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
HSCB | SNV | Missense_Mutation | novel | c.543N>A | p.Met181Ile | p.M181I | Q8IWL3 | protein_coding | tolerated(0.89) | benign(0.001) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
HSCB | SNV | Missense_Mutation | rs768337799 | c.295N>T | p.Arg99Cys | p.R99C | Q8IWL3 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
HSCB | SNV | Missense_Mutation | c.260C>T | p.Thr87Ile | p.T87I | Q8IWL3 | protein_coding | tolerated(0.22) | benign(0.014) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
HSCB | SNV | Missense_Mutation | c.539N>T | p.Ala180Val | p.A180V | Q8IWL3 | protein_coding | tolerated(0.17) | benign(0.213) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
HSCB | SNV | Missense_Mutation | novel | c.313N>A | p.Phe105Ile | p.F105I | Q8IWL3 | protein_coding | tolerated(0.38) | benign(0.376) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HSCB | SNV | Missense_Mutation | rs535969441 | c.296N>A | p.Arg99His | p.R99H | Q8IWL3 | protein_coding | deleterious(0.02) | benign(0.26) | TCGA-A5-A0GR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HSCB | SNV | Missense_Mutation | rs774561408 | c.362N>T | p.Ser121Leu | p.S121L | Q8IWL3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |